nuclear receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Einstein hosts one of the three inaugural MSTPs launched by the National Institutes of Health (NIH) in 1964. This fully-funded dual doctoral MD/PhD program provide integrated graduate and clinical training for aspiring physician-scientists. The MSTP includes waived tuition, a stipend, subsidized housing, and a sesquiennial retreat to the Edith Macy Conference Center. The first year of the program integrates medical school preclerkship curriculum with graduate school coursework and lab rotations. In the second year, trainees complete preclinical medical courses, take USMLE Step 1, and choose a PhD advisor based on lab rotations. Years three to five focus on PhD research, publication, and optional clinical activities, followed by intensive clinical clerkships in years six and seven after dissertation defense. While working in the lab, students engage in both pathology case studies and clinics to maintain clinical skills.
In clinical practice, this means that it takes 4 to 5 times the half-life for a drug's serum concentration to reach steady state after regular dosing is started, stopped, or the dose changed. So, for example, digoxin has a half-life (or t1/2) of 24–36 h; this means that a change in the dose will take the best part of a week to take full effect. For this reason, drugs with a long half-life (e.g., amiodarone, elimination t1/2 of about 58 days) are usually started with a loading dose to achieve their desired clinical effect more quickly.
Suppression of transthyretin production: Until 2018, liver and/or heart transplantation were the only ways to definitively treat TTR amyloidosis. Liver transplantation replaces the liver that is producing abnormal TTR proteins, and a heart transplantation replaces the heart with amyloid deposits for a non-diseased heart. Liver transplantation does not always halt the disease, and in some cases disease progression continues. Medications such as patisiran and inotersen can also decreases the activity of the transthyretin genes. These medications bind to the mRNA of transthyretin and prevent the production of the transthyretin protein, thus decreasing the overall amount of transthyretin that can accumulate in the body. Stabilization of abnormal transthyretin: There are medications that can stabilize the normally folded transthyretin, preventing misfolding and subsequent amyloid deposition. These medications include tafamidis, the non-steroidal anti-inflammatory drug (NSAID) diflunisal, and acoramidis. Tafamidis is a medication that binds to transthyretin and keeps it in its normal shape, stopping it from aggregating into amyloid fibrils. Diflunisal and acoramidis work in a similar manner to tafamidis in their ability to bind to and stabilize transthyretin. In a 30-month trial, tafamidis showed reduced mortality and reduced heart failure related hospitalizations compared to placebo. Tafamidis was also shown to improve functional capacity and quality of life in those with TTR amyloidosis.
=== Pharmacokinetics === Nedaplatin is administered in its active form and is removed from the bloodstream by the kidneys to leave the body via the urine. The recommended therapeutic dose of nedaplatin is 80–100 mg/m2 of body surface area. Optimal dosing is determined using measurements of unbound platinum concentrations following intravenous infusion together with an assessment of renal function using creatinine clearance. The dose can be estimated using Ishibashi’s formula: DoseNDP = AUC × CLNDP, where CLNDP = 0.0738 × creatinine clearance + 4.47 The precise mechanism of cellular uptake is not fully understood, and substantially less information is available compared with cisplatin. However, nedaplatin does not interact with the Oct2 transporter or apical multidrug and toxin extrusion (MATE) transporters, which may contribute to its lower accumulation in renal proximal tubules.
Cancer research progress:The largest study of whole cancer genomes reports 58 new mutational signatures and shows that for each organ "cancers have a limited number of common signatures and a long tail of rare signatures". A study reports presence of certain bacteria in the prostate and urine for aggressive forms of prostate cancer, with biomarker- and therapeutic potentials being unclear (18 Apr). 25 April Novel foods such as under-development cultured meat, existing microbial foods and ground-up insects are shown to have the potential to reduce environmental impacts by over 80% in a study. A review about meat and sustainability of food systems, animal welfare, and healthy nutrition concludes that its consumption has to be reduced substantially for sustainable consumption and names broad potential measures such as "restrictions or fiscal mechanisms". A new type of cell death 'erebosis' is reported after copper-dependent cell death was first reported the previous month. 26 April Scientists report the detection of purine and pyrimidine nucleobases in several meteorites, including guanine, adenine, cytosine, uracil and thymine, and claim that such meteoritic nucleobases could serve as "building blocks of DNA and RNA on the early Earth".
Sources: en.wikipedia.org
Ford's article in the Encyclopedia of Chromatography, theoretical studies indicate that at least for some systems, optimized overloaded elution chromatography offers higher throughput than displacement chromatography, though limited experimental tests suggest that displacement chromatography is superior (at least before consideration of regeneration time).
LSU rRNA subtypes have been called ribozymes because ribosomal proteins cannot bind to the catalytic site of the ribosome in this area (specifically the peptidyl transferase center, or PTC). The SSU rRNA subtypes decode mRNA in its decoding center (DC). Ribosomal proteins cannot enter the DC. The structure of rRNA is able to drastically change to affect tRNA binding to the ribosome during translation of other mRNAs. In 16S rRNA, this is thought to occur when certain nucleotides in the rRNA appear to alternate base pairing between one nucleotide or another, forming a "switch" that alters the rRNA's conformation. This process is able to affect the structure of the LSU and SSU, suggesting that this conformational switch in the rRNA structure affects the entire ribosome in its ability to match a codon with its anticodon in tRNA selection as well as decode mRNA.
== Principles of operation == ELSDs analyze solutes eluting out of the chromatographic column, both in LC and SFC. As the eluent exits the column's outlet into the detector inlet, it is mixed with an inert carrier gas (usually nitrogen) and forced through a nebulizer, which separates the liquid into fine aerosolized droplets. These droplets then pass into a heated drift tube, where the mobile phase solvent is evaporated off. As the mobile phase evaporates, the droplets become smaller and smaller until all that is left is minute particles of dried analyte. These particles are pushed through the drift tube by the carrier gas to the detection region. In this region, a beam of light crosses the column of analyte and the scattering of light is measured by a photodiode or photomultiplier tube. The detector's output is non-linear across more than one order of magnitude and proper calibration is required for quantitative analysis.
A text known as The Ritual of Embalming does describe some of the practical logistics of embalming; however, there are only two known copies and each is incomplete. With regards to mummification shown in images, there are apparently also very few. The tomb of Tjay, designated TT23, is one of only two known which show the wrapping of a mummy (Riggs 2014). Another text that describes the processes being used in the latter periods is Herodotus' Histories. Written in Book 2 of the Histories is one of the most detailed descriptions of the Egyptian mummification process, including the mention of using natron in order to dehydrate corpses for preservation. However, these descriptions are short and fairly vague, leaving scholars to infer the majority of the techniques that were used by studying mummies that have been unearthed. By utilizing current advancements in technology, scientists have been able to uncover a plethora of new information about the techniques used in mummification. A series of CT scans performed on a 2,400-year-old mummy in 2008 revealed a tool that was left inside the cranial cavity of the skull. The tool was a rod, made of an organic material, that was used to break apart the brain to allow it to drain out of the nose. This discovery helped to dispel the claim within Herodotus' works that the rod had been a hook made of iron. Earlier experimentation in 1994 by researchers Bob Brier and Ronald Wade supported these findings.
== Signs and symptoms == Symptoms vary according to individuals' hydration level and sensitivity to the rate and/or magnitude of decline of their blood glucose concentration. A crash is usually felt within four hours of heavy carbohydrate consumption. Along with the symptoms of hypoglycemia, symptoms of reactive hypoglycemia include:
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.